A gain of function variant in RGS18 candidate for a familial mild bleeding syndrome.

GTP-binding proteins blood platelets exome sequencing hemorrhage platelet function tests

Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
23 Oct 2024
Historique:
received: 11 09 2024
revised: 04 10 2024
accepted: 07 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: aheadofprint

Résumé

Inherited platelet diseases (IPDs) are bleeding disorders characterized by either defect in platelet count or in platelet function, the latter being less common and very heterogeneous. Numerous gene variants associated with abnormal receptors, granules, and signaling pathways have been reported. Despite significant advancements in our understanding, many patients still lack a precise diagnosis. To identify the genetic basis of a novel mild bleeding syndrome in a family exhibiting a selective defect of platelet aggregation. Our study included 6 family members across three generations, who displayed reduced platelet aggregation in response to ADP, PAR1-AP, arachidonic acid, and epinephrine, but not collagen. Platelet morphology, granule content and expression of major surface glycoproteins were all found to be normal. Whole exome sequencing was performed for affected and non-affected family members. We identified RGS18, which encodes the regulator of G protein signaling (RGS) 18, as a candidate gene for the platelet function defect observed in this family. The RGS18 protein serves as a crucial negative regulator of G protein-coupled receptor (GPCR) signaling and coordinates the signaling pathways of natural platelet inhibitors. The heterozygous RGS18 c.643C>T, p.Arg215* variant was found to co-segregate among all six affected subjects. Truncation at Arg215 removes the S216 and S218 phosphorylation sites, which are crucial regulatory domains for RGS18 activation. The impaired platelet function is thought to arise from excessive platelet downregulation due to constitutive activation of RGS18, resulting from a loss of association of the truncated form with the 14-3-3 protein.

Sections du résumé

BACKGROUND BACKGROUND
Inherited platelet diseases (IPDs) are bleeding disorders characterized by either defect in platelet count or in platelet function, the latter being less common and very heterogeneous. Numerous gene variants associated with abnormal receptors, granules, and signaling pathways have been reported. Despite significant advancements in our understanding, many patients still lack a precise diagnosis.
OBJECTIVES OBJECTIVE
To identify the genetic basis of a novel mild bleeding syndrome in a family exhibiting a selective defect of platelet aggregation.
PATIENTS/METHODS METHODS
Our study included 6 family members across three generations, who displayed reduced platelet aggregation in response to ADP, PAR1-AP, arachidonic acid, and epinephrine, but not collagen. Platelet morphology, granule content and expression of major surface glycoproteins were all found to be normal. Whole exome sequencing was performed for affected and non-affected family members.
RESULTS AND CONCLUSIONS CONCLUSIONS
We identified RGS18, which encodes the regulator of G protein signaling (RGS) 18, as a candidate gene for the platelet function defect observed in this family. The RGS18 protein serves as a crucial negative regulator of G protein-coupled receptor (GPCR) signaling and coordinates the signaling pathways of natural platelet inhibitors. The heterozygous RGS18 c.643C>T, p.Arg215* variant was found to co-segregate among all six affected subjects. Truncation at Arg215 removes the S216 and S218 phosphorylation sites, which are crucial regulatory domains for RGS18 activation. The impaired platelet function is thought to arise from excessive platelet downregulation due to constitutive activation of RGS18, resulting from a loss of association of the truncated form with the 14-3-3 protein.

Identifiants

pubmed: 39454878
pii: S1538-7836(24)00628-7
doi: 10.1016/j.jtha.2024.10.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Caroline Vayne (C)

Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France; INSERM U1327 ISCHEMIA, Université de Tours, Tours, France.

Maguelonne Roux (M)

Sorbonne Université, INSERM, UMR-S1166, Research Unit on Cardiovascular and Metabolic Diseases, Paris, France; Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.

Yves Gruel (Y)

INSERM U1327 ISCHEMIA, Université de Tours, Tours, France.

Marjorie Poggi (M)

INSERM, INRAe, C2VN, Aix-Marseille Univ, Marseille, France.

Claire Pouplard (C)

Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France; INSERM U1327 ISCHEMIA, Université de Tours, Tours, France.

Franck Peiretti (F)

INSERM, INRAe, C2VN, Aix-Marseille Univ, Marseille, France.

David-Alexandre Trégouët (DA)

Sorbonne Université, INSERM, UMR-S1166, Research Unit on Cardiovascular and Metabolic Diseases, Paris, France; University of Bordeaux, Bordeaux Population Health Research Center, INSERM, UMR 1219, Bordeaux, France.

Paquita Nurden (P)

Institut de Rythmologie et de Modélisation Cardiaque, Hôpital Xavier Arnozan, Pessac, France. Electronic address: paquita.nurden@gmail.com.

Marie-Christine Alessi (MC)

INSERM, INRAe, C2VN, Aix-Marseille Univ, Marseille, France; CRPP, CHU Timone, AP-HM, Marseille, France. Electronic address: marie-christine.alessi@univ-amu.fr.

Classifications MeSH